Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Preliminary Efficacy of CC312 in Relapsed/Refractory Autoimmune Diseases
NCT07193810Phase 1Recruiting
- Sponsor
- CytoCares
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CC312 in systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM) and systemic sclerosis (SSc), sponsored by CytoCares. Primary endpoints: Dose-limiting toxicity at 2 years and Adverse events and serious adverse events at 2 years. Started Sep 2025; status: recruiting.
02
Drugs
CC312
03
Conditions
systemic lupus erythematosus (SLE)idiopathic inflammatory myopathy (IIM)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07193810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07193810.